IndraLab

Statements


USP35 inhibits sensitivity ER breast cancer cells endocrine therapies. 1 / 1
| 1

eidos
"USP35 promoted the growth of ER + breast cancer in vitro and in vivo , and reduced the sensitivity of ER + breast cancer cells to endocrine therapies such as tamoxifen and fulvestrant ."